Johnson & Johnson said 20 million of the nation’s first COVID-19 single-dose vaccines would be available by the end of March on Tuesday – leading New York City to door-to-door service for a shut-in soon.
Mayor Bill de Blasio told reporters, “The big piece we want to get is really in-house vaccination, for people who can’t leave their homes.”
City Health Commissioner Dave Chokshi said Jammu and Kashmir’s testimony at the US House subcommittee on the development of the vaccine earlier in the day suggests that the Big Apple could begin home vaccinations early next month.
At the mayor’s briefing, he said, “We will be ready to do door-to-door vaccination very quickly for seniors throughout the month.”
“We hope to do so in March if everything goes according to plan with the FDA and on the basis of supplies allocated by the federal government,” Chokshi said, referring to the federal approval that the J&K vaccine has just got Is also needed.
City officials have shot Jammu and Kashmir – Who has applied for approval
From the Food and Drug Administration on February 4 – a game-changer because it requires only one dose and is much easier to store than its competitors’ vaccines.
Johnson & Johnson Veep dr. Richard Nettles – who has been involved in executions from coronovirus vaccine manufacturers – told members of the House Energy and Commerce Committee subcommittee on Oversight and Investigation that it has 4 million doses of shot that are now ready to ship.
“We will take 20 million doses of the available vaccine by the end of March, and we are ready to ship 4 million doses of the vaccine immediately to the emergency authority,” Nettles said.
By the end of June, the company hopes to produce 100 million doses.
Other manufacturers also contributed a portion of the total dose they expect to be available to the US.
By the end of March, Pfizer is expecting 120 million and Modern 100 million. By the end of May, the two companies are expected to have 200 million, and Modern should have 300 million by the end of July.
Novavax, which is yet to be approved, has stated that it will have a total of 110 million doses for the US by the third quarter of the year.
And the Oxford-AstraZeneca vaccine is the agreement to provide a total of 300 million doses.